Navigation Links
Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board
Date:7/27/2009

CAMBRIDGE, Mass., July 27 /PRNewswire/ -- Solace Pharmaceuticals, a private biotechnology company discovering and developing innovative treatments for pain, announced that David Julius, PhD, professor and chair of the department of physiology at the University of California, San Francisco, and a leading pioneer in the pathophysiology of pain, has joined Solace's scientific advisory board.

"We admire Professor Julius' pioneering research in the biology of pain and welcome his participation on Solace's scientific advisory board," said Dr. Eliot Forster, Solace's Chief Executive Officer. "We believe that Professor Julius' scientific interests are complementary to those of Solace, especially with respect to his recent work in glial cells, and we share his dedication to transforming biological insights into opportunities for drug discovery and development. We believe that Professor Julius' expertise will enrich our world-class scientific advisory board and we are pleased to have him join in our mission to discover and develop innovative treatments for pain."

Professor Julius comments, "Solace has staked out some very innovative approaches for targeting and tackling chronic pain. I look forward to working with an extraordinarily talented and diverse group of advisors to bring new ideas to the treatment of pain based on knowledge of its underlying mechanisms."

Professor Julius has made significant discoveries in the molecular basis of somatosensation - the process whereby we experience touch and temperature - and how somatosensation is altered in response to tissue or nerve injury. Professor Julius discovered that capsaicin, the main pungent ingredient in chili peppers, activates an excitatory ion channel, called TRPV1, on sensory nerve endings, and that TRPV1 functions as a molecular integrator of physical and chemical signals that regulate sensory neuron excitability under both normal and pathophysiological conditions. Following a similar paradigm, Professor Julius' research showed that a menthol receptor from primary sensory neurons is activated by cold thermal stimuli, and that the structure of this menthol/cold receptor, TRPM8, resembles that of TRPV1.

Professor Julius has received considerable recognition during his career. He has twice received awards from The McKnight Endowment Fund for Neuroscience, and in 2007, he was awarded the Edward M. Scolnick Prize in Neuroscience from The McGovern Institute for Brain Research at the Massachusetts Institute of Technology. Professor Julius has published widely in Nature, Cell, Science, and other prestigious publications. He earned his bachelor's degree at the Massachusetts Institute of Technology and his Ph.D. at the University of California, Berkeley. He is a member of the National Academy of Sciences.

About Solace Pharmaceuticals

Solace Pharmaceuticals discovers and develops innovative treatments for pain. Solace's research and development programs are focused on exploiting novel biological understanding of disease targets that play a role in the pathogenesis of pain and that have disease-modifying potential in two key areas: modulating the activity of glial cells and intervening in the tetrohydrobiopterin (BH4) pathway. SLC022, the company's lead drug candidate, is in phase II clinical development in patients with post-herpetic neuralgia (PHN). Solace's research and development are supported by a strong and expanding intellectual property portfolio. For more information, please visit the company's website at www.solacepharma.com.

    Contact:

    Marie Lossky, PhD
    Director, Business Development and
    Intellectual Property
    Solace Pharmaceuticals
    Phone: 617 401 4006
    Email: mlossky@solacepharma.com


'/>"/>
SOURCE Solace Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OncoGenex Pharmaceuticals Completes $9.5 Million Registered Direct Offering
2. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
3. Anadys Pharmaceuticals to Report Second Quarter 2009 Financial Results
4. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
5. NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients
8. OncoGenex Pharmaceuticals to Raise $9.5 Million Through Sale of Common Stock
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
10. VIA Pharmaceuticals Receives Anticipated Notice From NASDAQ
11. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016   BioInformant announces ... "Stem Cell Research Products, Opportunities, Tools, and Technologies – ... The ... the stem cell industry, BioInformant has more than a ... stem cell market, by stem cell type. This powerful ...
(Date:2/10/2016)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... Mitsui & Co. Ltd., its partner in the ... investing an additional CDN$25 million in the joint venture ... 30% to 40%.  Mitsui will also play a stronger ... Sarnia , providing dedicated resources alongside ...
(Date:2/10/2016)... , Feb.10, 2016 ASAE is introducing a ... Management Companies (AMC) the option of joining or renewing ... fee determined by staff size, every employee in any ... ASAE and reap all available member benefits.   ... new organizational membership options will allow organizations of any ...
(Date:2/10/2016)... , Feb. 10, 2016  Matchbook, Inc., a ... fast growing biotech companies, announced today the appointment ... Strategic Advisor. Jim brings nearly 25 years of ... procurement, having spent nearly two decades in executive ... and Procurement at Genzyme and, most recently headed ...
Breaking Biology Technology:
(Date:1/20/2016)... Minn. , Jan. 20, 2016   MedNet ... supports the entire spectrum of clinical research, is pleased ... 2015. MedNet,s significant achievements are the result of the ... iMedNet eClinical , it,s comprehensive, easy-to-use ... --> --> Key MedNet growth achievements ...
(Date:1/15/2016)... Jan. 15, 2016 Recent publicized breaches in ... find new ways to ensure data security and user ... and Android that ties a user,s ... it into a hardware authorization token. Customer service agents ... fingerprint on their KodeKey enabled device to verify their ...
(Date:1/11/2016)... SAN JOSE, Calif. , Jan. 11, 2016 /PRNewswire/ ... developer of human interface solutions, today announced that its ... display driver integration (TDDI) products won two separate categories ... including Best Mobile Innovator and Best Technology Breakthrough. The ... overall system cost, a simplified supply chain, thinner devices, ...
Breaking Biology News(10 mins):